Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the “Company” or “Kalytera”) today announced that the Company has elected to issue 2,923,491 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under the payments agreement with The Salzman Group previously announced on December 7, 2017 (the “December 2017 Agreement”) and the additional payments agreement announced on June 15, 2018 (the “June 2018 Agreement”).  Under the December 2017 Agreement, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease. Under the June 2018 Agreement, The Salzman Group and its affiliates provide general and administrative support services, study set-up work for planned studies in connection with use of CBD in treatment of GVHD, and research and development work in connection with Kalytera’s exclusive license of cannabidiol-naproxen conjugates for treatment of pain.

The invoiced amounts to be paid in Common Shares to The Salzman Group total to the amount of US$302,546 (or C$394,671.26 based on the daily average exchange rate for September 27, 2018 published by the Bank of Canada).  The number of Common Shares to be issued is based on a deemed issue price of C$0.135 per Common Share, being 90% of the closing price of the Common Shares on the TSXV on September 27, 2018, the trading day prior to the Company’s election to pay the invoiced amounts in Common Shares.  The Common Shares are expected to be issued to The Salzman Group on or about the date hereof.


About Kalytera Therapeutics
Kalytera Therapeutics, Inc. (“Kalytera”) is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease (“GVHD”) .

Kalytera also intends to develop a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a versatile compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera will seek to develop innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.

Cautionary Statements
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation in respect of its product candidate pipeline, planned clinical trials, regulatory approval prospects, intellectual property objectives and other statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that future clinical studies may not proceed as expected or may produce unfavourable results. Kalytera undertakes no obligation to comment on analyses, expectations or statements made by third-parties, its securities, or financial or operating results (as applicable). Although Kalytera believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Kalytera’s control. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. Kalytera disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Contact Information

Click here to connect with Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) for an Investor Presentation.

Source: globenewswire.com

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”) , a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2021 . All financial information is provided in U.S. dollars unless otherwise indicated.

1Q 2021 Financial Highlights (Unaudited)

Keep reading... Show less

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Harvest Health & Recreation Inc. (“Harvest” or the “Company”) (OTC: HRVSF) in connection with the proposed acquisition of the Company by Trulieve Cannabis Corp. (“Trulieve”) (OTC: TCNNF). Under the terms of the merger agreement, Harvest shareholders will receive 0.1170 shares of Trulieve common stock for each Harvest share that they own, representing implied per-share merger consideration of approximately $4.79 based upon Trulieve’s May 7, 2021 closing price of $40.92 . Upon consummation of the transaction, current Harvest shareholders will own only 26.7% of the issued and outstanding pro forma Trulieve shares.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, will speak at Canaccord Genuity’s 5th Annual Global Cannabis Conference on Tuesday, May 11, 2021 at 2:30 p.m. EDT.

Participants may access a live webcast of the presentation by going to the Upcoming Events page at thecronosgroup.com . A replay will be made available shortly following the live presentation.

Keep reading... Show less

Numinus and Multidisciplinary Association for Psychedelic Studies collaboration
will conduct follow-on Compassionate Access trial in real-world setting in Vancouver, Canada

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today congratulates the Multidisciplinary Association for Psychedelic Studies (MAPS) and the MAPP1 trial study team for their announcement of results from the Phase 3 randomized clinical trial of MDMA-assisted therapy for the treatment of severe post-traumatic stress disorder (PTSD).

Keep reading... Show less

Combined Company Will Maintain Industry Leading Scale in Retail, Cultivation & Production

Footprint Provides National Scale with a Deep Regional Focus in Attractive Markets

Keep reading... Show less